Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.65 USD
Change Today +0.44 / 0.78%
Volume 814.7K
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NVO) Snapshot

Open
$56.74
Previous Close
$56.21
Day High
$56.92
Day Low
$56.50
52 Week High
04/24/15 - $56.92
52 Week Low
01/6/15 - $41.72
Market Cap
147.3B
Average Volume 10 Days
1.1M
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
$0.73
Dividend Yield
1.29%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NVO)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NVO) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,957 Employees
Last Reported Date: 02/5/15
Founded in 1925

novo-nordisk a/s-spons adr (NVO) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NVO) Key Developments

Novo Nordisk Announces Saxenda Now Commercially Available in the United States

Novo Nordisk announced that Saxenda® (liraglutide [rDNA origin] injection) is now available in the United States. Saxenda® is the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults. It is indicated in the United States as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >30 kg/m2) or who are overweight (BMI >27 kg/m2) in the presence of at least one weight-related comorbid condition. Saxenda® was evaluated in the SCALE™ (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people) phase 3 clinical program, which involved more than 5,000 study participants who have obesity (BMI >30 kg/m2) or who are overweight (BMI >27 kg/m2) with weight-related comorbidities. Trial data showed that Saxenda®, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone. Saxenda® (liraglutide [rDNA origin] injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Novo Nordisk Opens Manufacturing Facility in Russia

Novo Nordisk announced the opening of a new plant located in Technopark Grabtsevo in the Kaluga region of Russia. The manufacturing facility will focus on the production of Penfill cartridges and FlexPen prefilled insulin injection pens for their commercialization in Russia. The company said that the new facility will be operating in accordance with current Good Manufacturing Practices. The opening of a manufacturing site in Russia is a sign of the company's interest in the expansion of its business in the Russian market. Production of insulin in the Russian facility is likely to boost availability of modern insulins for diabetes patients in Russia. The manufacturing facility will open in the Kaluga cluster where a total of 15 innovative medicines' development projects are in the process of being implemented. The clusters system, which is also supported through the Russian government's funding, represents a major opportunity for Russia to attract new investments in the life sciences sector and to strengthen the development of the pharmaceutical market in the country.

Novo Nordisk to Launch Novoeight® in the United States for People with Hemophilia A

Novo Nordisk announced the company will launch Novoeight® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight® offers purity, reliability, and enhanced portability, with the higher storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products up to 86 degrees F for 12 months.1 It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time.1 Novoeight® offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A.1 Novo Nordisk plans to make Novoeight® available by mid-April 2015. Hemophilia patients have unique, individualized needs, so it is critical for them to have access to different therapies. The US Food and Drug Administration (FDA) approved Novoeight® for use in adults and children with hemophilia A for the control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes based on results from the guardian trials one of the larger and most comprehensive clinical trial programs of a recombinant Factor VIII to date.1 Novoeight® is the latest hemophilia therapy from Novo Nordisk to build on the company's long-standing heritage in rare bleeding disorders, which began with the development of its first recombinant factor therapy more than 20 years ago. Novo Nordisk is confident in the Novoeight® offering and is supporting eligible patients who try the product with a satisfaction guarantee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $56.65 USD +0.44

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.07 USD +1.82
Actavis plc $295.41 USD -2.95
Amgen Inc $167.91 USD -1.26
Biogen Inc $401.71 USD -28.57
Bristol-Myers Squibb Co $65.80 USD -0.20
View Industry Companies
 

Industry Analysis

NVO

Industry Average

Valuation NVO Industry Range
Price/Earnings 34.8x
Price/Sales 10.2x
Price/Book 22.6x
Price/Cash Flow 27.3x
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.